<DOC>
	<DOCNO>NCT01092585</DOCNO>
	<brief_summary>Tesetaxel orally administer chemotherapy agent taxane class . This study undertaken evaluate efficacy safety tesetaxel administer second-line therapy patient advance melanoma normal serum lactate dehydrogenase ( LDH ) .</brief_summary>
	<brief_title>Tesetaxel Second-line Therapy Patients With Advanced Melanoma Normal Serum LDH</brief_title>
	<detailed_description />
	<mesh_term>Melanoma</mesh_term>
	<criteria>Primary inclusion criterion : Histologically confirm diagnosis melanoma Progressive disease surgically resectable , metastatic Stage IV disease Measurable disease ( revised RECIST ; Version 1.1 ) Serum LDH 1.1 time upper limit normal Eastern Cooperative Oncology Group performance status 0 1 Treatment 1 prior regimen ( include cytotoxic chemotherapy , immunotherapy , radiation therapy , cytokine , biologic , vaccine therapy ) firstline treatment metastatic disease ( Administration interleukin2 interferon adjuvant therapy allow consider determine 1 prior treatment regimen administer firstline treatment metastatic disease . ) Adequate bone marrow , hepatic , renal function , specify protocol At least 3 week recovery effect prior surgery therapy approve investigational agent Ability swallow oral soliddosage form medication Primary exclusion criterion : History presence brain metastasis leptomeningeal disease Primary ocular mucosal melanoma Significant medical disease cancer Organ allograft Presence neuropathy &gt; Grade 1 ( National Cancer Institute Common Toxicity Criteria [ NCI CTC ] ; Version 4.0 ) Prior treatment taxane tubulintargeted agent ( eg , indibulin ) vinca alkaloid Need continue regularlytaken medication potent inhibitor inducer CYP3A pathway Pglycoprotein activity</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2011</verification_date>
</DOC>